Valuation: Obalon Therapeutics Inc

Market Cap 1.45Cr 1.28Cr 1.2Cr 1.09Cr 2.06Cr 139.37Cr 2.07Cr 14Cr 5.61Cr 71Cr 5.43Cr 5.31Cr 228.57Cr P/E 2026 *
-3.17x
P/E 2027 * -2.59x
Enterprise Value 1.45Cr 1.28Cr 1.2Cr 1.09Cr 2.06Cr 139.37Cr 2.07Cr 14Cr 5.61Cr 71Cr 5.43Cr 5.31Cr 228.57Cr EV / Sales 2026 *
140x
EV / Sales 2027 * 72.3x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -

Financials

2026 *2027 *
Net sales 1L 91.43T 85.56T 77.55T 1L 99.29L 1L 10.28L 4L 50.65L 4L 4L 1.63Cr 2L 2L 2L 2L 3L 1.93Cr 3L 19.95L 8L 98.35L 8L 7L 3.16Cr
Net income -44.89L -39.85L -37.29L -33.8L -63.83L -43Cr -64.29L -4.48Cr -1.74Cr -22Cr -1.68Cr -1.65Cr -71Cr -78.46L -69.65L -65.18L -59.08L -1.12Cr -76Cr -1.12Cr -7.83Cr -3.04Cr -39Cr -2.95Cr -2.88Cr -124.04Cr
Net Debt - -
Logo Obalon Therapeutics Inc
Obalon Therapeutics, Inc. is a commercial-stage medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The Company's product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in obese patients. The Obalon balloon system is intended to be used as an adjunct to a moderate intensity diet and behavior modification program. All balloons must be removed six months after the first balloon is placed. The Obalon balloon system intends to provide patients and physicians with a reversible and repeatable weight loss solution in an outpatient setting, without altering patient anatomy or requiring surgery. The Company has received Premarket approval (PMA) for its Obalon balloon system based on the results of its United States pivotal clinical trial, referred to as the SMART trial.
Employees
-
Sector
-